378 / 1266
EGFR inhibitors show efficacy
in vitro
but are ineffective in patients
Van den Bent et. al., J Clin Oncol, 27(8); 2009
Randomised phase II
study in recurrent GBM:
PFS-6
Erlotinib 11%
TMZ 24%
Erlotinib
TMZ
Perreboormtet. al., J Neurooncol, 2010
Phase II study of erlotinib with radiotherapy and temozolomide in
newly diagnosed GBM:
•
No improvement in outcome compared to historical controls
•
Worse toxicity